연구성과로 돌아가기

2023 연구자 정보 (1075 / 1135)

※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
Author Name 제1저자 여부 ⓘ 교신저자 여부 ⓘ Address ResearcherID ORCID Paper Title WoS Edition 최상위 JCR(%) WoS Category Related Email
Enzinger, Peter C.
(Enzinger, PC) ⓘ 		Dana Farber Brigham Canc Ctr, Boston, MA USA ⓘ
ⓘ
ⓘ 		[JCR상위 74.7] Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/Gastroesophageal Adenocarcinoma ⓘ SCIE ⓘ 74.7 ONCOLOGY ⓘ ykkang@amc.seoul.kr; ⓘ
Goh, Myung Ji
(Goh, MJ) ⓘ 		Sungkyunkwan Univ, Samsung Med Ctr, Dept Med, Sch Med, Seoul, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 74.7] Radiotherapy trend in elderly hepatocellular carcinoma: retrospective analysis of patients diagnosed between 2005 and 2017 ⓘ ESCI ⓘ 74.7 ONCOLOGY ⓘ hee.ro.park@samsung.com; ⓘ
Gold, Philip J.
(Gold, PJ) ⓘ 		Swedish Canc Inst, Seattle, WA USA ⓘ
ⓘ
ⓘ 		[JCR상위 74.7] Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/Gastroesophageal Adenocarcinoma ⓘ SCIE ⓘ 74.7 ONCOLOGY ⓘ ykkang@amc.seoul.kr; ⓘ
Hochster, Howard S.
(Hochster, HS) ⓘ 		Yale Sch Med, New Haven, CT USA
Rutgers Canc Inst New Jersey, New Brunswick, NJ USA ⓘ
ⓘ
ⓘ 		[JCR상위 74.7] Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/Gastroesophageal Adenocarcinoma ⓘ SCIE ⓘ 74.7 ONCOLOGY ⓘ ykkang@amc.seoul.kr; ⓘ
Juergens, Rosalyn A.
(Juergens, RA) ⓘ 		McMaster Univ, Juravinski Canc Ctr, Hamilton, ON, Canada ⓘ
ⓘ 		0000-0001-8627-4704
Juergens, Rosalyn ⓘ 		[JCR상위 74.7] Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/Gastroesophageal Adenocarcinoma ⓘ SCIE ⓘ 74.7 ONCOLOGY ⓘ ykkang@amc.seoul.kr; ⓘ
Kaminker, Patrick
(Kaminker, P) ⓘ 		MacroGenics, Rockville, MD USA ⓘ
ⓘ
ⓘ 		[JCR상위 74.7] Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/Gastroesophageal Adenocarcinoma ⓘ SCIE ⓘ 74.7 ONCOLOGY ⓘ ykkang@amc.seoul.kr; ⓘ
Kang, Woo Youl
(Kang, WY) ⓘ 		Kyungpook Natl Univ Hosp, Dept Clin Pharmacol, Daegu, South Korea
Natl Inst Food & Drug Safety Evaluat, Dept Innovat Prod Support, Clin Trial Dossier Evaluat Team, Cheongju 28159, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 74.7] Comparative Pharmacokinetic Profiles of a Novel Low-Dose Micronized Formulation of Raloxifene 45 mg (AD-101) and the Conventional Raloxifene 60 mg in Healthy Subjects
[JCR상위 83.5] Fed and fasted bioequivalence assessment of two formulations of extended-release fixed-dose combination dapagliflozin/metformin (10/1,000 mg) tablets in healthy subjects ⓘ 		SCIE
ESCI ⓘ 		74.7 PHARMACOLOGY & PHARMACY ⓘ yry@knu.ac.kr;
yry@knu.ac.kr;wintersj@knu.ac.kr; ⓘ
Kelly, Ronan J.
(Kelly, RJ) ⓘ 		Baylor Univ, Med Ctr, Dallas, TX USA ⓘ
ⓘ
ⓘ 		[JCR상위 74.7] Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/Gastroesophageal Adenocarcinoma ⓘ SCIE ⓘ 74.7 ONCOLOGY ⓘ ykkang@amc.seoul.kr; ⓘ
Kim, Sunnie
(Kim, S) ⓘ 		Georgetown Univ, Lombardi Comprehens Canc Ctr, Washington, DC USA
Univ Colorado, Canc Ctr, Aurora, CO USA ⓘ 		J-2750-2012
Kim, Tae-You ⓘ
ⓘ 		[JCR상위 74.7] Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/Gastroesophageal Adenocarcinoma ⓘ SCIE ⓘ 74.7 ONCOLOGY ⓘ ykkang@amc.seoul.kr; ⓘ
Kim, Yeul Hong
(Kim, YH) ⓘ 		Korea Univ, Anam Hosp, Seoul, South Korea
Korea Univ, Anam Hosp, Coll Med, Dept Internal Med,Div Oncol Hematol, Seoul, South Korea ⓘ
ⓘ 		0000-0002-2555-2333
Kim, Yeul Hong ⓘ 		[JCR상위 74.7] Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/Gastroesophageal Adenocarcinoma
[JCR상위 5.6] Genome-wide association study of lung adenocarcinoma in East Asia and comparison with a European population ⓘ 		SCIE ⓘ 5.6 ONCOLOGY
MULTIDISCIPLINARY SCIENCES ⓘ 		ykkang@amc.seoul.kr;
jianxin.shi@nih.gov;qingl@mail.nih.gov; ⓘ
Lacy, Jill
(Lacy, J) ⓘ 		Yale Sch Med, New Haven, CT USA ⓘ
ⓘ
ⓘ 		[JCR상위 74.7] Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/Gastroesophageal Adenocarcinoma ⓘ SCIE ⓘ 74.7 ONCOLOGY ⓘ ykkang@amc.seoul.kr; ⓘ
Lagow, Errin
(Lagow, E) ⓘ 		Guardant Hlth, Redwood City, CA USA ⓘ
ⓘ
ⓘ 		[JCR상위 74.7] Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/Gastroesophageal Adenocarcinoma ⓘ SCIE ⓘ 74.7 ONCOLOGY ⓘ ykkang@amc.seoul.kr; ⓘ
Li, Daner
(Li, D) ⓘ 		MacroGenics, Rockville, MD USA ⓘ
ⓘ
ⓘ 		[JCR상위 74.7] Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/Gastroesophageal Adenocarcinoma ⓘ SCIE ⓘ 74.7 ONCOLOGY ⓘ ykkang@amc.seoul.kr; ⓘ
Marrone, Kristen A.
(Marrone, KA) ⓘ 		Johns Hopkins Univ, Baltimore, MD USA ⓘ
ⓘ
ⓘ 		[JCR상위 74.7] Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/Gastroesophageal Adenocarcinoma ⓘ SCIE ⓘ 74.7 ONCOLOGY ⓘ ykkang@amc.seoul.kr; ⓘ
Moore, Paul A.
(Moore, PA) ⓘ 		MacroGenics, Rockville, MD USA ⓘ
ⓘ
ⓘ 		[JCR상위 74.7] Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/Gastroesophageal Adenocarcinoma ⓘ SCIE ⓘ 74.7 ONCOLOGY ⓘ ykkang@amc.seoul.kr; ⓘ
페이지 이동: